NCT05464836 2025-11-26
Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL
M.D. Anderson Cancer Center
Phase 2 Terminated
M.D. Anderson Cancer Center
AbbVie
Bristol-Myers Squibb
Pharmacyclics LLC.
Ono Pharmaceutical Co. Ltd